Supra‐Annular Versus Intra‐Annular Devices for Transcatheter Aortic Valve‐in‐Valve Replacement: The PANDORA International Registry
Journal of the American Heart Association · 21.04.2026 · 15 (8)
DOI: 10.1161/jaha.125.046180 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 21.04.2026. Verfasst von Antonio Popolo Rubbio und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Interventional Cardiology IRCCS Policlinico San Donato San Donato Milanese Italy. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis, Aortic Valve, Aortic Valve Stenosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
As transcatheter aortic valve replacement (TAVR) expands to younger, lower‐risk populations, the need for repeat procedures due to valve degeneration is expected to increase. TAVR‐in‐TAVR has emerged as a feasible strategy, although outcomes across supra‐annular (SAV) and intra‐annular (IAV) valve combinations remain unclear. The PANDORA (Supra‐Annular Versus Intra‐Annular Devices for TAVR‐in‐TAVR) international registry study assessed safety, hemodynamic performance, and clinical outcomes of TAVR‐in‐TAVR according to prosthetic configurations.
Methods
From an international multicenter registry (2011–2024), 172 TAVR‐in‐TAVR cases were identified among ≈30 000 TAVR procedures, with a median interval of 1401 days. Patients were stratified into 4 groups: SAV‐IAV (n=32), SAV‐SAV (n=29), IAV‐SAV (n=74), and IAV‐IAV (n=37).
Results
CoreValve/Evolut (49.4%) and Edwards SAPIEN (35.5%) were the most frequent index prostheses, whereas the second valve was mainly Edwards SAPIEN (60.5%), followed by Evolut (35.5%) and Myval/Octacor (4.0%). Structural valve deterioration was the leading failure mechanism (77.9%), while nonstructural valve deterioration dysfunction, alone or combined with structural valve deterioration, occurred in 40.7%. Overall Valve Academic Research Consortium 3 technical success was 91.3%, numerically highest in SAV‐IAV and IAV‐SAV ( P =0.090). Thirty‐day device success was 68%, also higher in SAV‐IAV (75.9%, P =0.301), mainly influenced by elevated residual gradients (≥20 mm Hg in 12.7%) and the 30‐day mortality rate (7.3%). At 1 year, the IAV‐IAV group showed the numerically lowest freedom from death and heart failure hospitalization (76.1%, P =0.734). Male sex and chronic kidney disease independently predicted death at follow‐up.
Conclusions
TAVR‐in‐TAVR is feasible with generally favorable outcomes, although clinical and procedural profiles vary by the different prosthesis combinations. These findings highlight the need for further studies to refine device selection strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical and Interventional Cardiology IRCCS Policlinico San Donato San Donato Milanese Italy.
- Erasmus University Medical Center Rotterdam the Netherlands.
- Groupe CardioVasculaire Interventionnel Clinique Pasteur Toulouse France.
- Montefiore Medical Center New York NY USA.
- Rigshospitalet, Copenhagen University Hospital Copenhagen Denmark.
- Humanitas Research Center, IRCCS Rozzano Milan Italy.
ORCID-Profile: Antonio Popolo Rubbio, Antonio Sisinni, Enrico Criscione, Enrico Poletti, Nicolas Van Mieghem, Gaspare S Cannone, Didier Tchétché, Azeem Latib, Andrea Scotti, Ole De Backer, Michele Morosato, Ignacio A Santos, Matjaz Bunc, David Hildick-Smith, Joachim Schofer, Christina Brinkmann, Kush P Patel, Andreas Baumbach, Luca Testa
Zitieren
APA
Popolo Rubbio, A., Sisinni, A., Criscione, E., Poletti, E., Van Mieghem, N., Cannone, G. S., Tchétché, D., Latib, A., Scotti, A., De Backer, O., Morosato, M., Regazzoli, D., Santos, I. A., Voskuil, M., Bunc, M., Hildick-Smith, D., Schofer, J., Brinkmann, C., Patel, K. P., …, & Testa, L. (2026). Supra‐Annular Versus Intra‐Annular Devices for Transcatheter Aortic Valve‐in‐Valve Replacement: The PANDORA International Registry. Journal of the American Heart Association, 15(8). https://doi.org/10.1161/jaha.125.046180
Vancouver
Popolo Rubbio A, Sisinni A, Criscione E, Poletti E, Van Mieghem N, Cannone GS, et al. Supra‐Annular Versus Intra‐Annular Devices for Transcatheter Aortic Valve‐in‐Valve Replacement: The PANDORA International Registry. Journal of the American Heart Association. 2026;15(8). doi:10.1161/jaha.125.046180
BibTeX
@article{PopoloRubbio2026,
author = {Popolo Rubbio, Antonio and Sisinni, Antonio and Criscione, Enrico and Poletti, Enrico and Van Mieghem, Nicolas and Cannone, Gaspare S and Tchétché, Didier and Latib, Azeem and Scotti, Andrea and De Backer, Ole and Morosato, Michele and Regazzoli, Damiano and Santos, Ignacio A and Voskuil, Michiel and Bunc, Matjaz and Hildick-Smith, David and Schofer, Joachim and Brinkmann, Christina and Patel, Kush P and Baumbach, Andreas and Bedogni, Francesco and Testa, Luca},
title = {Supra‐Annular Versus Intra‐Annular Devices for Transcatheter Aortic Valve‐in‐Valve Replacement: The PANDORA International Registry},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {8},
doi = {10.1161/jaha.125.046180}
}
EUVIMED